SubsidieMeestersDrug solution for bone fracture nonunions
Genera Research aims to develop OSTEOGROW-C, a novel biological drug using patients' blood to treat bone fracture nonunion, promising effective regeneration and reduced complications.
Projectdetails
Introduction
Bone fracture nonunion (FNU) is one of the leading unmet orthopaedic clinical needs, resulting in billions of healthcare costs annually without any drug approved by regulatory agencies for this debilitating indication. Due to considerable shortcomings of the current best practices in treating bone FNUs, patients are facing increased risks and morbidity.
Current Market Limitations
The market has available only bone substitutes and enhancers with limited clinical efficiency, highlighting an essential need for more effective therapies. Genera Research is on its way to filling the gap with its globally patented OSTEOGROW-C product: a novel biological drug transforming patients’ blood into bone.
Project Overview
The proposed OSTEOforUNION project aims to develop and commercialize OSTEOGROW-C, an innovative drug for bone regeneration. OSTEOGROW-C is a novel treatment option for bone FNUs, an implant composed of an active substance - recombinant human bone morphogenetic protein 6 (rhBMP6) incorporated in an autologous blood coagulum (ABC) where tricalcium phosphate (TCP) ceramics is added as a compression resistant matrix (CRM).
Benefits of OSTEOGROW-C
This combination forms a personalized implant that catalyzes bone growth at the implantation site. It is easily prepared in the operating room from the patient's blood without the need for a painful bone harvesting procedure, as in current treatment practices. This approach reduces associated complications and morbidities, including:
- Donor site pain
- Infection
- Nerve injuries
- Blood loss
- Iliac wing fracture
Additionally, it minimizes related healthcare costs.
Market Potential
OSTEOGROW-C targets the global FNU market, which serves 6 million patients yearly. Key overlapping markets include:
- Fracture Fixation
- Orthobiologics
- Bone Grafts
- BMP
OSTEOGROW-C's unique stance promises to revolutionize the FNU market.
Market Entry Strategy
The initial market entry will concentrate on the markets in the EU, with 180,000 diagnosed long bone FNUs in Europe annually. Simultaneously, OSTEOGROW-C will be launched in the US, addressing more than 120,000 bone FNUs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 2.499.999 |
Tijdlijn
| Startdatum | 1-1-2025 |
| Einddatum | 31-12-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- GENERA ISTRAZIVANJA DRUSTVO S OGRANICENOM ODGOVORNOSCU ZA PROIZVODNJU BIOTEHNOLOSKIH PROIZVODApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONSTRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes. | ERC POC | € 150.000 | 2022 | Details |
Regenerative Stenting for Osteoporotic Vertebral Fracture RepairRESTORE aims to revolutionize osteoporotic vertebral fracture treatment by using 3D-printed biodegradable stents and thermoresponsive hydrogels for personalized bone regeneration and repair. | ERC COG | € 2.039.473 | 2024 | Details |
A 3D-printable biomimetic bone regeneration materialPRIOBONE aims to validate a novel 3D-printable, bone-mimetic material for critical-size bone defects, offering a customizable, cost-effective solution to improve healing outcomes. | ERC POC | € 150.000 | 2024 | Details |
Self-feeding implants to improve and accelerate tissue healing using nutritional nanoparticlesThe NutriBone project aims to develop a patented self-feeding bone implant that enhances long-term viability and reduces failure rates for large bone defects through glycogen-based glucose release. | ERC POC | € 150.000 | 2024 | Details |
Transforming bone cancer therapy with composite biomaterials encapsulating plasma-generated RONS
TRANSFORMER aims to develop a novel therapy combining cold atmospheric plasma-treated hydrogels with biomaterials for simultaneous osteosarcoma treatment and bone regeneration, enhancing patient outcomes.
Regenerative Stenting for Osteoporotic Vertebral Fracture Repair
RESTORE aims to revolutionize osteoporotic vertebral fracture treatment by using 3D-printed biodegradable stents and thermoresponsive hydrogels for personalized bone regeneration and repair.
A 3D-printable biomimetic bone regeneration material
PRIOBONE aims to validate a novel 3D-printable, bone-mimetic material for critical-size bone defects, offering a customizable, cost-effective solution to improve healing outcomes.
Self-feeding implants to improve and accelerate tissue healing using nutritional nanoparticles
The NutriBone project aims to develop a patented self-feeding bone implant that enhances long-term viability and reduces failure rates for large bone defects through glycogen-based glucose release.